drugset / Trial / NCT04217291

The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus

NCT04217291

Phase 2 Completed 200 enrolled Suzhou Yabao Pharmaceutical R&D Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study in patients with type 2 diabetes mellitus (T2DM).

Timeline

Start
2019-12-10
Primary completion
2021-07-09
Completion
2021-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2608204 Small molecule 80 mg Oral
Subject LY2608204 Small molecule 160 mg Oral
Subject LY2608204 Small molecule 240 mg Oral